Neuren Pharmaceuticals Limited
NURPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1,727 | $1,599 | $2,731 | $3,171 |
| - Cash | $6 | $3 | $3 | $17 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1,721 | $1,596 | $2,729 | $3,154 |
| Revenue | $28 | $193 | $24 | $169 |
| % Growth | -85.3% | 691.3% | -85.6% | – |
| Gross Profit | $13 | $177 | $6 | $153 |
| % Margin | 47.3% | 92.2% | 26.5% | 90.7% |
| EBITDA | $11 | $175 | $4 | $151 |
| % Margin | 38.6% | 91% | 16.8% | 89.4% |
| Net Income | $15 | $134 | $8 | $109 |
| % Margin | 53.2% | 69.6% | 33% | 64.7% |
| EPS Diluted | 0.12 | 1.03 | 0.061 | 0.83 |
| % Growth | -88.3% | 1,580.3% | -92.6% | – |
| Operating Cash Flow | $128 | $9 | -$21 | $140 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $128 | $9 | -$21 | $140 |